Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aldosterone synthase inhibition in humans
Michel Azizi, Laurence Amar, Joël Ménard
Nephrology Dialysis Transplantation (2012) Vol. 28, Iss. 1, pp. 36-43
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis
Nancy J. Brown
Nature Reviews Nephrology (2013) Vol. 9, Iss. 8, pp. 459-469
Open Access | Times Cited: 355
New Approaches in the Treatment of Hypertension
Suzanne Oparil, Roland E. Schmieder
Circulation Research (2015) Vol. 116, Iss. 6, pp. 1074-1095
Closed Access | Times Cited: 256
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
Mason W. Freeman, Yuan‐Di C. Halvorsen, William Marshall, et al.
New England Journal of Medicine (2022) Vol. 388, Iss. 5, pp. 395-405
Open Access | Times Cited: 215
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani, et al.
The Lancet (2023) Vol. 403, Iss. 10424, pp. 379-390
Open Access | Times Cited: 70
Novel RAAS agonists and antagonists: clinical applications and controversies
César A. Romero, Marcelo Orías, Matthew R. Weir
Nature Reviews Endocrinology (2015) Vol. 11, Iss. 4, pp. 242-252
Open Access | Times Cited: 136
Acute Effects of Lysergic Acid Diethylamide on Circulating Steroid Levels in Healthy Subjects
Petra Strajhar, Yasmin Schmid, Evangelia Liakoni, et al.
Journal of Neuroendocrinology (2016) Vol. 28, Iss. 3
Open Access | Times Cited: 126
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
Rosario Pivonello, Rosario Ferrigno, Maria Cristina De Martino, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 105
Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
Pantelis Sarafidis, Fotini Iatridi, Charles J. Ferro, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 11, pp. 1885-1907
Open Access | Times Cited: 26
Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
Stefan R. Bornstein, Dick de Zeeuw, Hiddo J.L. Heerspink, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 6, pp. 2128-2138
Open Access | Times Cited: 10
Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents
Juan Tamargo, J. Segura, Luís M. Ruilope
Expert Opinion on Pharmacotherapy (2014) Vol. 15, Iss. 5, pp. 605-621
Closed Access | Times Cited: 77
Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2)
Katrijn Bogman, Dietmar Schwab, Marie‐Laure Delporte, et al.
Hypertension (2016) Vol. 69, Iss. 1, pp. 189-196
Open Access | Times Cited: 74
Aldosterone Synthase Inhibitors as Promising Treatments for Mineralocorticoid Dependent Cardiovascular and Renal Diseases
Qingzhong Hu, Lina Yin, Rolf W. Hartmann
Journal of Medicinal Chemistry (2014) Vol. 57, Iss. 12, pp. 5011-5022
Closed Access | Times Cited: 58
Aldosterone synthase inhibitors in cardiovascular and renal diseases
Pawel Namsolleck, T Unger
Nephrology Dialysis Transplantation (2014) Vol. 29, Iss. suppl 1, pp. i62-i68
Open Access | Times Cited: 53
Aldosterone Production and Signaling Dysregulation in Obesity
Andrea Vecchiola, Carlos F. Lagos, Cristián A. Carvajal, et al.
Current Hypertension Reports (2016) Vol. 18, Iss. 3
Closed Access | Times Cited: 50
Human cytochrome P450 enzymes 5–51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition – toxic effects and benefits
Slobodan Rendić, F. Peter Guengerich
Drug Metabolism Reviews (2018) Vol. 50, Iss. 3, pp. 256-342
Open Access | Times Cited: 48
Role of Aldosterone in Renal Fibrosis
Aanchal Shrestha, Ruochen Che, Aihua Zhang
Advances in experimental medicine and biology (2019), pp. 325-346
Closed Access | Times Cited: 47
Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects
Joël Ménard, Dean F. Rigel, Catherine E. Watson, et al.
Journal of Translational Medicine (2014) Vol. 12, Iss. 1
Open Access | Times Cited: 47
Aldosterone synthase inhibitors in hypertension: current status and future possibilities
Milan Hargovan, Albert Ferro
JRSM Cardiovascular Disease (2014) Vol. 3
Open Access | Times Cited: 45
Clinical Utility of Osilodrostat in Cushing’s Disease: Review of Currently Available Literature
Milica Perosevic, Nicholas A. Tritos
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 1303-1312
Open Access | Times Cited: 11
Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys
Rainer E. Martin, Johannes D. Aebi, Benoit Hornsperger, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 20, pp. 8054-8065
Closed Access | Times Cited: 39
Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice
Oliver Adam, Christina Zimmer, Nina Hanke, et al.
Journal of Molecular and Cellular Cardiology (2015) Vol. 85, pp. 140-150
Open Access | Times Cited: 35
Future drug discovery in renin-angiotensin-aldosterone system intervention
María Tamargo, Juan Tamargo
Expert Opinion on Drug Discovery (2017), pp. 1-22
Closed Access | Times Cited: 34
Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy
Emma Magavern, Vikas Kapil, Manish Saxena, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 4, pp. 784-793
Closed Access | Times Cited: 3
Aldosterone synthase inhibition in chronic kidney disease
Marieta Theodorakopoulou, Fotini Iatridi, Pantelis Sarafidis
Current Opinion in Nephrology & Hypertension (2025)
Closed Access
Breaking down resistance: novel aldosterone synthase inhibitors in the management of resistant hypertension
CY Hung, Cyril Kocherry, George Casella
Journal of Hypertension (2025)
Closed Access
Page 1 - Next Page

Scroll to top